From the Institute of Clinical Chemistry, University Hospital of Zurich, 8091 Zurich, Switzerland,; the Competence Center for Systems Physiology and Metabolic Diseases, ETH and University of Zurich, 8091 Zurich, Switzerland.
From the Institute of Clinical Chemistry, University Hospital of Zurich, 8091 Zurich, Switzerland,; the Center for Integrative Human Physiology, University of Zurich, 8091 Zurich, Switzerland.
J Biol Chem. 2011 Mar 11;286(10):7744-7754. doi: 10.1074/jbc.M110.193524. Epub 2011 Jan 5.
High density lipoproteins (HDL) and apolipoprotein A-I (apoA-I) must leave the circulation and pass the endothelium to exert their atheroprotective actions in the arterial wall. We previously demonstrated that the transendothelial transport of apoA-I involves ATP-binding cassette transporter (ABC) A1 and re-secretion of lipidated particles. Transendothelial transport of HDL is modulated by ABCG1 and the scavenger receptor BI (SR-BI). We hypothesize that apoA-I transport is started by the ABCA1-mediated generation of a lipidated particle which is then transported by ABCA1-independent pathways. To test this hypothesis we analyzed the endothelial binding and transport properties of initially lipid-free as well as prelipidated apoA-I mutants. Lipid-free apoA-I mutants with a defective carboxyl-terminal domain showed an 80% decreased specific binding and 90% decreased specific transport by aortic endothelial cells. After prior cell-free lipidation of the mutants, the resulting HDL-like particles were transported through endothelial cells by an ABCG1- and SR-BI-dependent process. ApoA-I mutants with deletions of either the amino terminus or both the amino and carboxyl termini showed dramatic increases in nonspecific binding but no specific binding or transport. Prior cell-free lipidation did not rescue these anomalies. Our findings of stringent structure-function relationships underline the specificity of transendothelial apoA-I transport and suggest that lipidation of initially lipid-free apoA-I is necessary but not sufficient for specific transendothelial transport. Our data also support the model of a two-step process for the transendothelial transport of apoA-I in which apoA-I is initially lipidated by ABCA1 and then further processed by ABCA1-independent mechanisms.
高密度脂蛋白 (HDL) 和载脂蛋白 A-I (apoA-I) 必须离开循环系统并穿过内皮细胞,才能在动脉壁中发挥其抗动脉粥样硬化作用。我们之前的研究表明,apoA-I 的跨内皮转运涉及 ATP 结合盒转运蛋白 (ABC) A1 和脂质化颗粒的再分泌。HDL 的跨内皮转运受 ABCG1 和清道夫受体 BI (SR-BI) 调节。我们假设 apoA-I 的转运是由 ABCA1 介导的脂质化颗粒的生成开始的,然后通过 ABCA1 非依赖性途径进行转运。为了验证这一假设,我们分析了最初无脂质和预脂质化 apoA-I 突变体的内皮结合和转运特性。具有缺陷羧基末端结构域的无脂质 apoA-I 突变体与主动脉内皮细胞的特异性结合减少了 80%,特异性转运减少了 90%。突变体在细胞外脂质化后,生成的 HDL 样颗粒通过 ABCG1 和 SR-BI 依赖性途径在内皮细胞中转运。缺失氨基末端或氨基末端和羧基末端的 apoA-I 突变体的非特异性结合显著增加,但无特异性结合或转运。细胞外脂质化不能挽救这些异常。我们严格的结构-功能关系的研究结果强调了跨内皮 apoA-I 转运的特异性,并表明最初无脂质的 apoA-I 的脂质化对于特异性跨内皮转运是必要的,但不是充分的。我们的数据还支持 apoA-I 跨内皮转运的两步模型,其中 apoA-I 首先被 ABCA1 脂质化,然后通过 ABCA1 非依赖性机制进一步加工。